Cardiff Oncology
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cardiff Oncology generated cash of -$30,887,000, which is more than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore $5,308,000.
Cash Flow
| 2014 | -12.72M | -299.79K | 14.48M |
|---|---|---|---|
| 2015 | -22.11M | -2.23M | 64.55M |
| 2016 | -31.04M | -24.83M | 2.30M |
| 2017 | -23.28M | 23.96M | -6.37M |
| 2018 | -13.2M | 23K | 16.40M |
| 2019 | -13.26M | -68K | 12.07M |
| 2020 | -16.31M | -211.88K | 137.31M |
| 2021 | -23.04M | -131.44M | 35.45M |
| 2022 | -33.82M | 38.14M | 75K |
| 2023 | -30.88M | 36.19M | 0 |
CRDF Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 16.34M | 11.94M | 130.98M | 10.19M | 11.45M | 8.22M | 13.91M | 67.49M | 27.29M | 25.83M |
Operating activities | ||||||||||
Net income | -41.44M | -38.70M | -28.29M | -19.30M | -16.41M | -16.46M | -24.90M | -39.20M | -27.47M | -14.32M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 398K | 236K | 451K | 466.00K | 494K | 859K | 1.24M | 1.07M | 378.71K | 234.81K |
Stock-based compensation expense | 4.50M | 4.25M | 3.23M | 1.76M | 885K | 0 | 4.01M | 7.50M | 3.94M | 2.07M |
| Deferred income tax benefit | 4.50M | 4.25M | 3.23M | 1.76M | 885K | 0 | 4.01M | 7.50M | 3.94M | 2.07M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 483K | -236K | -215K | -116.97M | -35.72M | 19.26M | 23.36K | -1.72K | -42.04K | 22.3K |
Inventories | 0 | 0 | 0 | -1.15B | -1.41B | -255.62M | 0 | -2.15B | -361.49M | -631.88M |
Accounts payable | 2.83M | 1.34M | 719K | 1.27B | 1.45B | 236.48M | -2.94B | 2.15B | 361.43M | 632.29M |
Cash generated by operating activities | -30.88M | -33.82M | -23.04M | -16.31M | -13.26M | -13.2M | -23.28M | -31.04M | -22.11M | -12.72M |
Investing activities | ||||||||||
Purchases Of Investments | -70.08M | -91.23M | -174.38M | 0 | 0 | -31.5K | -8.80M | -24.01M | 0 | 0 |
Investments In Property Plant And Equipment | -582K | -892K | -205K | -211.88K | -68K | -5.1K | -100K | -823K | -2.24M | -363.29K |
Acquisitions Net | 0 | -114K | 205K | 0 | 0 | 5.1K | 109.90M | 809.73M | 7.6K | 0 |
Cash generated by investing activities | 36.19M | 38.14M | -131.44M | -211.88K | -68K | 23K | 23.96M | -24.83M | -2.23M | -299.79K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 75K | 34.18M | 137.31M | 8.81M | 0 | 11.72M | 0 | 61.21M | 0 |
Payments for dividends | 0 | -414K | 0 | 0 | -24.24M | 0 | -24.24M | 0 | -24.24M | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -305K | 0 | -1.37M | -17.23M | -351.00K | 1.08M | -14.48M |
Cash used in financing activities | 0 | 75K | 35.45M | 137.31M | 12.07M | 16.40M | -6.37M | 2.30M | 64.55M | 14.48M |
Net Change In Cash | 5.30M | 4.40M | -119.03M | 120.78M | -1.25M | 3.22M | -5.68M | -53.57M | 40.19M | 1.45M |
Cash at end of period | 21.65M | 16.34M | 11.94M | 130.98M | 10.19M | 11.45M | 8.22M | 13.91M | 67.49M | 27.29M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |